Abstract Background Wild type RAS (RAS-wt) status is predictive of the activities of the anti-
epidermal growth factor receptor (EGFR) monoclonal antibodies cetuximab (C) and …

Despite new and more effective cytotoxic chemotherapy, limitations to conventional agents
have been reached in a subset of patients with advanced colorectal cancer (CRC). The …

Colorectal cancer (CRC) is a frequently lethal disease with heterogeneous outcomes and
drug responses. To resolve inconsistencies among the reported gene expression–based …

Background In the TRIBE study, FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and
irinotecan) plus bevacizumab significantly improved progression-free survival of patients …

Purpose The MOSAIC (Multicenter International Study of Oxaliplatin/Fluorouracil/Leucovorin
in the Adjuvant Treatment of Colon Cancer) study has demonstrated 3-year disease-free …

Purpose BRAF V600E mutation is seen in 5% to 8% of patients with metastatic colorectal
cancer (CRC) and is associated with poor prognosis. Vemurafenib, an oral BRAF V600 …

Purpose To evaluate dabrafenib, a selective BRAF inhibitor, combined with trametinib, a
selective MEK inhibitor, in patients with BRAF V600–mutant metastatic colorectal cancer …

Background: We sought to clarify the prognostic impact of primary tumor location in
metastatic colorectal cancer (mCRC). Methods: We evaluated the association between …

Purpose: BRAF-mutant metastatic colorectal cancer (mCRC) forms an aggressive subset of
colorectal cancer with minimal response to selective RAF inhibitors. Preclinical data show …

Colorectal cancer is a serious health problem, a challenge for research, and a model for
studying the molecular mechanisms involved in its development. According to its incidence …